We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > PD-L1 inhibitor

News List

Human trial data of oral small molecule PD-1/PD-L1 inhibitors were first released PharmaSources/Xiaoyaowan
December 02, 2021
Recently, Incyte of the United States reported the Phase I clinical data of oral small molecule PD-L1 inhibitor INCB086550 in Journal for ImmunoTherapy of Cancer.
Adlai Nortye Announces First Patient Dosed in Phase I Clinical Trial of the orally available, small-molecule PD-L1 inhibitor AN4005 for Advanced Tumors prnasia
January 06, 2022
Adlai Nortye Ltd. ("Adlai Nortye"), a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies, announced that the first patient was dosed in the Phase I clinical trial...
Maxinovel's Orally Active PD-L1 Inhibitor Demonstrating Similar Efficacy to PD-L1 Antibody Durvalumab firstwordpharma
April 21, 2019
Maxinovel Pharmaceuticals, Inc. presented in the 2019 AACR the head to head comparison of its orally active small ……